CY1114215T1 - Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης - Google Patents
Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσηςInfo
- Publication number
- CY1114215T1 CY1114215T1 CY20131100703T CY131100703T CY1114215T1 CY 1114215 T1 CY1114215 T1 CY 1114215T1 CY 20131100703 T CY20131100703 T CY 20131100703T CY 131100703 T CY131100703 T CY 131100703T CY 1114215 T1 CY1114215 T1 CY 1114215T1
- Authority
- CY
- Cyprus
- Prior art keywords
- active ingredients
- pharmaceutical solutions
- solid pressure
- pressure inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η εφεύρεση αφορά τη χρήση μίας σύνθεσης διαλύματος για υπό πίεση εισπνευστήρες μετρούμενης δόσης, οι οποίοι είναι σε θέση να παρέχουν θεραπευτικές δόσεις δύο ή περισσοτέρων δραστικών συστατικών ουσιών εις τον πνεύμονα, για την παραγωγή ενός φαρμάκου για την πρόληψη ή τη θεραπευτική αγωγή μίας σοβαρής βρογχοπνευμονικής πάθησης, όπου το σύνολο των δραστικών συστατικών ουσιών είναι πλήρως διαλυμένο εντός της σύνθεσης, όπως επίσης οι δύο ή περισσότερες δραστικές συστατικές ουσίες χορηγούνται με ουσιαστικά την ίδια κατανομή μεγέθους σωματιδίων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/408,026 US20060257324A1 (en) | 2000-05-22 | 2006-04-21 | Pharmaceutical solution formulations for pressurised metered dose inhalers |
EP07724357.4A EP2010190B1 (en) | 2006-04-21 | 2007-04-19 | Pharmaceutical solution formulations for pressurised metered dose inhalers |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114215T1 true CY1114215T1 (el) | 2016-08-31 |
Family
ID=38230023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100703T CY1114215T1 (el) | 2006-04-21 | 2013-08-14 | Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης |
Country Status (21)
Country | Link |
---|---|
US (4) | US20060257324A1 (el) |
EP (1) | EP2010190B1 (el) |
JP (1) | JP5289306B2 (el) |
KR (1) | KR101311662B1 (el) |
CN (4) | CN101389341A (el) |
AU (1) | AU2007241336C1 (el) |
BR (1) | BRPI0709510A2 (el) |
CA (1) | CA2649556C (el) |
CY (1) | CY1114215T1 (el) |
DK (1) | DK2010190T3 (el) |
EA (1) | EA016262B1 (el) |
ES (1) | ES2424753T3 (el) |
HR (1) | HRP20130835T1 (el) |
ME (1) | ME02342B (el) |
MX (1) | MX2008013460A (el) |
PL (1) | PL2010190T3 (el) |
PT (1) | PT2010190E (el) |
RS (1) | RS52940B (el) |
SI (1) | SI2010190T1 (el) |
WO (1) | WO2007121913A2 (el) |
ZA (1) | ZA200808965B (el) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
PL207377B1 (pl) * | 2001-03-30 | 2010-12-31 | Jagotec Ag | Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
EP1746981B1 (en) * | 2004-05-13 | 2008-08-13 | CHIESI FARMACEUTICI S.p.A. | Medicinal aerosol formulation products with improved chemical stability |
GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
CN103462943A (zh) * | 2005-07-15 | 2013-12-25 | Map药物公司 | 在离散的吸入粒子中结合的多种活性药物成分及其制剂 |
EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
US20100291221A1 (en) * | 2009-05-15 | 2010-11-18 | Robert Owen Cook | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
WO2010138158A1 (en) * | 2009-05-15 | 2010-12-02 | Map Pharmaceuticals, Inc. | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
LT2435023T (lt) | 2009-05-29 | 2016-09-26 | Pearl Therapeutics, Inc. | Kompozicijos, skirtos ilgai veikiančių muskarininių antagonistų ir ilgai veikiančių beta-2-adrenerginio receptoriaus agonistų pristatymui į plaučius, ir susiję būdai bei sistemos |
EP2440196A4 (en) * | 2009-06-09 | 2013-01-02 | Elevation Pharmaceuticals Inc | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC |
GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
GB0918149D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
ES2468835T3 (es) * | 2009-12-23 | 2014-06-17 | Chiesi Farmaceutici S.P.A. | Terapia combinada para EPOC |
GEP20166479B (en) | 2009-12-23 | 2016-05-25 | Chiesi Farma Spa | Aerosol formulation for copd |
KR101795348B1 (ko) * | 2009-12-23 | 2017-12-01 | 키에시 파르마슈티시 엣스. 피. 에이. | Copd용 에어로졸 제제 |
TWI495468B (zh) * | 2009-12-23 | 2015-08-11 | Chiesi Farma Spa | 治療慢性阻塞性肺病(copd)之醫藥組成物 |
WO2011101114A2 (en) * | 2010-02-16 | 2011-08-25 | Teva Branded Pharmaceutical Products R&D, Inc. | An inhalable pharmaceutical composition |
WO2011136752A1 (en) * | 2010-04-26 | 2011-11-03 | Mahmut Bilgic | Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases |
WO2011136754A1 (en) * | 2010-04-26 | 2011-11-03 | Mahmut Bilgic | A medicament developed for the treatment of respiratory diseases |
CN102266560A (zh) * | 2010-06-04 | 2011-12-07 | 北京阜康仁生物制药科技有限公司 | 一种用于治疗气喘的药物组合物 |
JP2013531056A (ja) * | 2010-07-16 | 2013-08-01 | シプラ・リミテッド | R(+)ブデソニド及び1以上の気管支拡張剤を含む医薬組成物 |
GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
WO2014144894A1 (en) | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
MX368835B (es) | 2013-12-30 | 2019-10-18 | Chiesi Farm Spa | Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol. |
US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
GB201515310D0 (en) * | 2015-08-27 | 2015-10-14 | Jagotec Ag | Pharmaceutical composition |
EP3383366B2 (en) | 2015-12-04 | 2024-06-05 | Mexichem Fluor S.A. de C.V. | Pharmaceutical composition |
WO2018051132A1 (en) * | 2016-09-19 | 2018-03-22 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
BR112019005168A2 (pt) | 2016-09-19 | 2019-06-11 | Mexichem Fluor Sa De Cv | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica |
CN114272238A (zh) | 2016-09-19 | 2022-04-05 | 墨西哥氟石股份公司 | 药物组合物 |
ES2841649T5 (es) * | 2016-09-19 | 2024-04-24 | Mexichem Fluor Sa De Cv | Composición farmacéutica |
AU2017328905C1 (en) | 2016-09-19 | 2020-08-06 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
EP3801457A1 (en) | 2018-06-04 | 2021-04-14 | Lupin Inc. | Stable pharmaceutical compositions for pressurized metered dose inhalers |
WO2020152548A1 (en) * | 2019-01-24 | 2020-07-30 | Glenmark Pharmaceuticals Limited | Stable aerosol inhalation compositions of formoterol |
AU2019477296A1 (en) | 2019-12-02 | 2022-04-14 | Chiesi Farmaceutici S.P.A. | Stainles steel can for pressurised metered dose inhalers |
CN111467498A (zh) * | 2020-05-14 | 2020-07-31 | 王兆霖 | 药物组合物制剂 |
US11844793B2 (en) | 2020-09-29 | 2023-12-19 | Aerorx Therapeutics Llc | Liquid formulations of indacaterol |
GB2614901A (en) | 2022-01-21 | 2023-07-26 | Nanopharm Ltd | Inhalable formulations |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE128350T1 (de) | 1991-12-12 | 1995-10-15 | Glaxo Group Ltd | Pharmazeutische aerosolformulierung. |
HU227519B1 (en) * | 1991-12-18 | 2011-07-28 | Astra Ab | Synergic pharmaceutical composition containing combination of formoterol and budesonide |
US5483953A (en) * | 1995-04-08 | 1996-01-16 | The United States Of America As Represented By The Secretary Of The Navy | Aerosol dispensing apparatus for dispensing a medicated vapor into the lungs of a patient |
US6461591B1 (en) * | 1997-02-05 | 2002-10-08 | Jago Research Ag | Medical aerosol formulations |
US20010031244A1 (en) * | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
US6173047B1 (en) * | 1997-08-11 | 2001-01-09 | Dale W. Malik | System and method for temporary voicemail service |
US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
JP4570251B2 (ja) * | 1998-07-24 | 2010-10-27 | ヤゴテック アーゲー | 医薬用エーロゾル製剤 |
NZ509489A (en) * | 1998-08-04 | 2002-10-25 | Jago Res A | Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil |
DZ2947A1 (fr) * | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
SE9900833D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
EP1248597B1 (en) | 1999-12-24 | 2005-03-30 | Glaxo Group Limited | Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
IT1317846B1 (it) * | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
EA005179B1 (ru) * | 2000-05-22 | 2004-12-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Стабильные фармацевтические препараты в виде растворов для дозированных ингаляторов под давлением |
US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
US6451287B1 (en) * | 2000-05-26 | 2002-09-17 | Smithkline Beecham Corporation | Fluorinated copolymer surfactants and use thereof in aerosol compositions |
FI20002216A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
US20040197271A1 (en) * | 2001-03-20 | 2004-10-07 | Kunka Robert Leonard | Inhalation drug combinations |
US20030178022A1 (en) * | 2001-12-21 | 2003-09-25 | Chiesi Farmaceutici S.P.A. | Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators |
EP1415647A1 (en) * | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
NZ535018A (en) | 2002-03-01 | 2007-02-23 | Chiesi Farmaceutici S | Pharmaceutical aerosol formulation containing formoterol, and its method of production |
EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
WO2004019985A1 (en) * | 2002-08-29 | 2004-03-11 | Cipla Ltd | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
US7459146B2 (en) * | 2003-05-30 | 2008-12-02 | 3M Innovative Properties Company | Stabilized aerosol dispersions |
EP2275479A1 (en) * | 2003-08-11 | 2011-01-19 | Glaxo Group Limited | Pharmaceutical metered dose inhaler and methods relating thereto |
WO2005077339A1 (en) * | 2004-02-10 | 2005-08-25 | E.I. Dupont De Nemours And Company | Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister |
EP1595531A1 (en) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
CA2559062A1 (en) | 2004-03-09 | 2005-09-22 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
ES2317306T3 (es) * | 2004-10-12 | 2009-04-16 | Generics (Uk) Limited | Procedimiento para la preparacion de formulaciones en aerosol en suspension, en el que las particulas se forman por precipitacion dentro de un frasco de aerosol. |
WO2006088894A2 (en) * | 2005-02-15 | 2006-08-24 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
US10098837B2 (en) * | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
-
2006
- 2006-04-21 US US11/408,026 patent/US20060257324A1/en not_active Abandoned
-
2007
- 2007-04-19 BR BRPI0709510-4A patent/BRPI0709510A2/pt not_active Application Discontinuation
- 2007-04-19 WO PCT/EP2007/003420 patent/WO2007121913A2/en active Application Filing
- 2007-04-19 AU AU2007241336A patent/AU2007241336C1/en active Active
- 2007-04-19 DK DK07724357.4T patent/DK2010190T3/da active
- 2007-04-19 ES ES07724357T patent/ES2424753T3/es active Active
- 2007-04-19 CN CNA2007800069518A patent/CN101389341A/zh active Pending
- 2007-04-19 EP EP07724357.4A patent/EP2010190B1/en active Active
- 2007-04-19 PT PT77243574T patent/PT2010190E/pt unknown
- 2007-04-19 KR KR1020087018846A patent/KR101311662B1/ko active IP Right Grant
- 2007-04-19 CA CA2649556A patent/CA2649556C/en active Active
- 2007-04-19 PL PL07724357T patent/PL2010190T3/pl unknown
- 2007-04-19 MX MX2008013460A patent/MX2008013460A/es active IP Right Grant
- 2007-04-19 RS RS20130386A patent/RS52940B/en unknown
- 2007-04-19 JP JP2009505773A patent/JP5289306B2/ja active Active
- 2007-04-19 SI SI200731304T patent/SI2010190T1/sl unknown
- 2007-04-19 ME MEP-2016-22A patent/ME02342B/me unknown
- 2007-04-19 CN CN2012103537724A patent/CN102908308A/zh active Pending
- 2007-04-19 CN CN201610483860.4A patent/CN106074359A/zh active Pending
- 2007-04-19 CN CN201610428382.7A patent/CN105963249A/zh active Pending
- 2007-04-19 EA EA200802012A patent/EA016262B1/ru not_active IP Right Cessation
-
2008
- 2008-10-20 ZA ZA2008/08965A patent/ZA200808965B/en unknown
- 2008-10-21 US US12/255,075 patent/US20090130026A1/en not_active Abandoned
-
2013
- 2013-08-14 CY CY20131100703T patent/CY1114215T1/el unknown
- 2013-09-09 HR HRP20130835TT patent/HRP20130835T1/hr unknown
-
2016
- 2016-11-17 US US15/353,978 patent/US10525006B2/en active Active
-
2019
- 2019-11-20 US US16/689,611 patent/US11213485B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114215T1 (el) | Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης | |
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
CY1116926T1 (el) | Συνθεση για εισπνοη που περιεχει ακλιδινιο για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας | |
CY1111159T1 (el) | Πυκνα διαλυματα μεθοτρεξατης | |
EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
BR112014012815A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
CU20110100A7 (es) | Tratamiento de pirfenidona para pacientes con función hepática atípica | |
AR059723A2 (es) | Composicion de altas dosis de ibandronato | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
CR20110243A (es) | Tratamiento de pirfenidona para pacientes con función hepática. | |
DE602006017728D1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo |